Indaptus Therapeutics Enhances Patent Protections Worldwide
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a forward-thinking biotechnology firm focused on innovative cancer therapies and viral infections, is proud to announce a significant expansion of its patent portfolio. This expansion secures vital approvals in key regions, including China, Japan, and Israel, for its groundbreaking Decoy platform technology.
The newly granted patents emphasize the application of Decoy bacteria compositions, specifically targeting viruses like the Hepatitis B virus (HBV) and human immunodeficiency virus (HIV), both of which represent critical ongoing health challenges on a global scale. Furthermore, these patents encompass novel combination therapies that integrate both established and experimental treatments.
Highlighting the Global Health Crisis
Chronic infections from HBV are particularly pressing in Asian countries, underlining an urgent need for new and effective treatment options. For instance:
- Approximately 87 million individuals in China are living with chronic HBV, making up nearly one-third of all global cases.
- In Japan, the chronic HBV population is estimated to range from 1.1 to 1.2 million.
- Recent statistics indicate that in a single year, HBV caused about 1.1 million deaths worldwide, primarily due to complications like cirrhosis and liver cancer.
Despite current treatment methods, the demand for innovative therapies remains critical to enhance long-standing health outcomes and combat these illnesses effectively.
A Distinct Methodology for Treatment of Infectious Diseases and Cancer
Preclinical findings reveal that the Decoy bacteria developed by Indaptus, which are comprised of harmless and weakened bacterial strains, can significantly activate the immune response against chronic infections such as HBV and HIV in standard laboratory settings.
Furthermore, the Decoy platform has delivered promising results in cancer treatment models, showcasing the potential for single-agent efficacy as well as successful combination strategies. One candidate from this series, Decoy20, is currently undergoing evaluation in a Phase 1 clinical trial in the United States, specifically targeting patients with advanced cancer cases.
These newly secured patents not only bolster Indaptus’ position in the immunotherapy sector, but they also represent a strategic advancement in the ongoing development of innovative treatment strategies for infectious diseases and cancer.
About Indaptus Therapeutics
Indaptus Therapeutics is building on a century's worth of discovery in immunotherapy. The company champions a revolutionary approach grounded in the principle that effective immune response against tumors and viral infections necessitates a diverse array of immune-activating signals, which can be safely administered via intravenous (i.v.) methods. Indaptus’ patented technology harnesses unique strains of neither living nor pathogenic Gram-negative bacteria, geared towards activating multiple immune pathways.
The Decoy product candidates are characterized by well-considered designs aimed at minimizing i.v. toxicity while maximizing the potential for activating innate and adaptive immune responses. This technology has demonstrated significant efficacy against various forms of cancer, including pancreatic and colorectal tumors, as well as notable results against chronic HBV and HIV infections in controlled studies. The Decoy candidates have successfully showcased combined efficacy when administered with other therapies such as low-dose chemotherapy and checkpoint inhibitors.
For more detailed information regarding their innovative work in the biomedical field, interested parties can access www.indaptusrx.com.
Frequently Asked Questions
What is Indaptus Therapeutics known for?
Indaptus Therapeutics specializes in developing innovative treatments for cancer and viral infections, particularly through its Decoy platform technology.
What recent patents has Indaptus secured?
The company has recently secured patent approvals for its Decoy platform in China, Japan, and Israel, focusing on treating Hepatitis B and HIV.
Why are the Decoy bacteria important?
They stimulate the immune system to fight chronic infections and have shown significant promise in both infectious diseases and cancer studies.
Where is Decoy20 currently being tested?
Decoy20 is currently undergoing evaluation in a Phase 1 clinical trial in the United States.
How does Indaptus’ approach differ from traditional treatments?
Indaptus integrates direct immune stimulation using non-pathogenic bacteria, aiming for multi-faceted immune activation to combat complex diseases.
